Beyond the Molecule: Human Factors Engineering as the Competitive Edge in Drug-Device Combination Products
The molecule isn’t the differentiator anymore. The device is.
What this whitepaper covers: How an integrated CDMO turns device usability into commercial advantage for self-administered drug-device combination products.
Whitepaper Abstract:
For a generation, the molecule was the hardest part of drug development. Not anymore.
As rival therapies converge on similar efficacy, the device experience decides whether patients start, stay, and succeed on treatment.
But most adherence failures aren’t drug failures — they’re usability failures. Without a validated risk analysis or a plan to survive scale-up, poor design shows up as missed doses, mislabeled device defects, and lost revenue.
An integrated CDMO changes that – combining human factors, device engineering, and manufacturing under one quality system so usability holds from first-in-human through commercial supply.
This paper covers:
- why the patient population has fundamentally changed
- what poor usability actually costs a brand
- how the 2023 FDA guidance redefined a “critical task”
- how usability becomes commercial differentiation, not just compliance
- why integration is what protects it at scale